Determination of HER-2/Neu status in hepatocellular carcinoma cases.

Specific chromosome abnormalities and genetic changes in hepatocellular carcinoma (HCC) have been demonstrated by conventional cytogenetic studies or molecular cytogenetic approaches like comparative genomic hybridization and loss of heterozygosity analyses. HER-2/Neu amplification and expression has been studied as a molecular target for treatment of HCC, and there are conflicting results. We aimed to determine HER-2/Neu status in archive materials of HCC patients by fluorescence in situ hybridization (FISH). Among the 35 patients, 2 had HER-2/Neu amplification and 3 had increased chromosome 17 copy number. All these patients had grade 2 or 3 tumor with a diameter of 3-12 cm. We conclude that although HER-2/Neu amplification is not the primary mechanism in the development of liver tumors, it might play a role in one of the steps of multistage carcinogenesis.

[1]  H. Karakayalı,et al.  Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients , 2008, Pathology & Oncology Research.

[2]  M. Bavbek,et al.  Chromosome 1p36 and 22qter deletions in paraffin block sections of intracranial meningiomas , 2008, Pathology & Oncology Research.

[3]  P. Schirmacher,et al.  Dysregulation of growth factor signaling in human hepatocellular carcinoma , 2006, Oncogene.

[4]  S. Francque,et al.  Viral hepatitis and hepatocellular carcinoma , 2005, World journal of surgical oncology.

[5]  W. Cong,et al.  Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma , 2005, Journal of Clinical Pathology.

[6]  M. Tibiletti.  Specificity of interphase fluorescence in situ hybridization for detection of chromosome aberrations in tumor pathology. , 2004, Cancer Genetics and Cytogenetics.

[7]  M. Anzola.  Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis , 2004, Journal of viral hepatitis.

[8]  Bi-Jun Huang,et al.  Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[9]  F. Kurokawa,et al.  Numerical Aberrations of Chromosomes 16, 17, and 18 in Hepatocellular Carcinoma (A FISH and FCM Analysis of 20 Cases) , 2004, Digestive Diseases and Sciences.

[10]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[11]  M. Hung,et al.  Strategies to target HER2/neu overexpression for cancer therapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  M. Fiorentino,et al.  Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  O. Dietze,et al.  Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.

[14]  H. Hsu,et al.  HER‐2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti‐HER‐2/neu regulation of cell growth and chemosensitivity , 2002, Cancer.

[15]  M. Monden,et al.  Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma , 2001, British Journal of Cancer.

[16]  A. Bernheim,et al.  Interphase cytogenetic studies of human hepatocellular carcinomas by fluorescent in situ hybridization , 1996, Hepatology.